Erschienen in:

19.08.2024 | Breast Oncology

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study

verfasst von: Kendra M. Parrish, DO, Samantha M. Thomas, MS, Sara B. Cartwright, MD, Astrid Botty van den Bruele, MD, Rebecca Zasloff, BS, Gayle A. DiLalla, MD, Maggie L. DiNome, MD, Carolyn S. Menendez, MD, Laura H. Rosenberger, MD, MS, Hannah E. Woriax, MD, E. Shelley Hwang, MD, MPH, Jennifer K. Plichta, MD, MS, Akiko Chiba, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting of IBC is not well described. We evaluated overall survival (OS) between IBC patients and non-IBC patients who achieved pCR.

Methods

Adult females diagnosed in 2010–2018 with clinical prognostic stage III unilateral invasive breast cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery were selected from the National Cancer Database. Unadjusted OS from surgery was estimated using the Kaplan–Meier method, and log-rank tests were used to compare groups. Cox proportional hazard models were used to estimate the association of study groups with OS after adjustment for available covariates.

Results

The study included 38,390 patients; n = 4600 (12.0%) IBC and n = 33,790 (88.0%) non-IBC. Overall pCR rates were lower for IBC compared with non-IBC (20.7% vs. 23.3%; p < 0.001). Among those achieving pCR, 5-year mortality was higher for IBC patients (16.4%, 95% confidence interval [CI] 13.9–19.1%) versus non-IBC patients (9.1%, 95% CI 8.4–9.8%; log-rank p < 0.001). Among all patients achieving pCR, IBC remained associated with worse OS compared with non-IBC (hazard ratio 1.48, 95% CI 1.19–1.85; p < 0.001).

Conclusion

We found a lower pCR rate and worse OS in IBC patients compared with non-IBC stage III patients. Despite effective systemic therapies, achieving a pCR for IBC patients may not carry the same prognostic impact compared with non-IBC stage III patients.

Inflammatory Breast Cancer. National Cancer Institute. Updated 6 Jan 2016. Available at: https://www.cancer.gov/types/breast/ibc-fact-sheet.

Abraham HG, Xia Y, Mukherjee B, Merajver SD. Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database. Breast Cancer Res Treat. 2021;185(1):229–38. https://doi.org/10.1007/s10549-020-05938-2.CrossRefPubMed

Fouad TM, Ueno NT, Yu RK, et al. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): a comprehensive analysis of the IBC registry at the University of Texas MD Anderson cancer center. PLoS One. 2018;13(9):e0204372. https://doi.org/10.1371/journal.pone.0204372.CrossRefPubMedPubMedCentral

Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4. https://doi.org/10.1245/s10434-010-0985-4.CrossRefPubMed

Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res. 2005;65(6):2170–8. https://doi.org/10.1158/0008-5472.Can-04-4115.CrossRefPubMed

Di Bonito M, Cantile M, Botti G. Pathological and molecular characteristics of inflammatory breast cancer. Transl Cancer Res. 2019;8(Suppl 5):S449-s456. https://doi.org/10.21037/tcr.2019.03.24.CrossRefPubMedPubMedCentral

Hester RH, Hortobagyi GN, Lim B. Inflammatory breast cancer: early recognition and diagnosis is critical. Am J Obstet Gynecol. 2021;225(4):392–6. https://doi.org/10.1016/j.ajog.2021.04.217.CrossRefPubMed

Cancer Stat Facts: Female Breast Cancer. Available at: https://seer.cancer.gov/statfacts/html/breast.html.

Laohavinij S, Ruikchuchit K, Maneechavakajorn J. Survival and prognostic factors of stage I-III breast cancer. J Med Assoc Thai. 2013;96(Suppl 3):S23-34.PubMed

10.

Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2006;24(13):2019–27. https://doi.org/10.1200/JCO.2005.04.1665.CrossRefPubMed

11.

Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15(7):2483–93. https://doi.org/10.1200/JCO.1997.15.7.2483.CrossRefPubMed

12.

Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol. 2020;6(5):676–84. https://doi.org/10.1001/jamaoncol.2019.6650.CrossRefPubMed

13.

Grimm MJK, Schnell P, Pariser A, Gatti-Mays M, VanDeusen J, Williams N, Stover D, Sardesai A, Wesolowski R, Sudheendra P, Ramaswamy B, Un Park K, Jhawar S, Kerger A, Cherian M. Outcome differences amongst stage-matched inflammatory vs non-inflammatory breast cancer patients. J Natl Compr Cancer Netw. 2022. https://doi.org/10.6004/jnccn.2021.7279.CrossRef

14.

Pan E, Tung L, Ragab O, et al. Inflammatory breast cancer outcomes in a contemporary series. Anticancer Res. 2017;37(9):5057–63. https://doi.org/10.21873/anticanres.11922.CrossRefPubMedPubMedCentral

15.

Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 2015;38(3):242–7. https://doi.org/10.1097/COC.0b013e3182937921.CrossRefPubMedPubMedCentral

16.

Adesoye T, Everidge S, Chen J, et al. Low rates of local-regional recurrence among inflammatory breast cancer patients after contemporary trimodal therapy. Ann Surg Oncol. 2023;30(10):6232–40. https://doi.org/10.1245/s10434-023-13906-5.CrossRefPubMed

17.

Biswas T, Jindal C, Fitzgerald TL, Efird JT. Pathologic complete response (pCR) and survival of women with inflammatory breast cancer (IBC): an analysis based on biologic subtypes and demographic characteristics. Int J Environ Res Public Health. 2019;16(1):124. https://doi.org/10.3390/ijerph16010124.CrossRefPubMedPubMedCentral

18.

Zhou J, Yan Y, Guo L, et al. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer. Saudi Med J. 2014;35(11):1324–30.PubMedPubMedCentral

19.

Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the national cancer database. Br J Surg. 2020;107(8):1033–41. https://doi.org/10.1002/bjs.11469.CrossRefPubMed

20.

Li J, Xia Y, Wu Q, et al. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: a population-based study from the SEER program. Oncotarget. 2017;8(30):49370–9. https://doi.org/10.18632/oncotarget.17217.CrossRefPubMedPubMedCentral

21.

Wang L, Asirvatham JR, Ma Y, Reisenbichler ES, Jorns JM. HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. Breast J. 2021;27(8):631–7. https://doi.org/10.1111/tbj.14241.CrossRefPubMed

22.

Spring LM, Fell G, Arfe A, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838–48. https://doi.org/10.1158/1078-0432.CCR-19-3492.CrossRefPubMedPubMedCentral

23.

von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804. https://doi.org/10.1200/jco.2011.38.8595.CrossRef

24.

Adesoye T, Irwin S, Sun SX, Lucci A, Teshome M. Contemporary surgical management of inflammatory breast cancer: a narrative review. Chin Clin Oncol. 2021;10(6):57. https://doi.org/10.21037/cco-21-113.CrossRefPubMed

25.

Faldoni FLC, Rainho CA, Rogatto SR. Epigenetics in inflammatory breast cancer: biological features and therapeutic perspectives. Cells. 2020;9(5):1164. https://doi.org/10.3390/cells9051164.CrossRefPubMedPubMedCentral

26.

Liang X, Vacher S, Boulai A, et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer. Breast Cancer Res. 2018;20(1):88. https://doi.org/10.1186/s13058-018-1007-x.CrossRefPubMedPubMedCentral

27.

Lerebours F, Vacher S, Guinebretiere JM, et al. Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer? J Adv Res. 2021;28:77–85. https://doi.org/10.1016/j.jare.2020.08.009.CrossRefPubMed

28.

Bertucci F, Boudin L, Finetti P, et al. Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. Oncoimmunology. 2021;10(1):1929724. https://doi.org/10.1080/2162402X.2021.1929724.CrossRefPubMedPubMedCentral

Titel: Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study
verfasst von: Kendra M. Parrish, DO
Samantha M. Thomas, MS
Sara B. Cartwright, MD
Astrid Botty van den Bruele, MD
Rebecca Zasloff, BS
Gayle A. DiLalla, MD
Maggie L. DiNome, MD
Carolyn S. Menendez, MD
Laura H. Rosenberger, MD, MS
Hannah E. Woriax, MD
E. Shelley Hwang, MD, MPH
Jennifer K. Plichta, MD, MS
Akiko Chiba, MD
Publikationsdatum: 19.08.2024
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 12/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-024-16026-w

Effectiveness of Prehabilitation Modalities on Postoperative Outcomes Following Colorectal Cancer Surgery: A Systematic Review of Randomised Controlled Trials

Open Access
Colorectal Cancer

ASO Visual Abstract: Temporal Trends in Survival Outcomes for Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy: A 14-Year Analysis

ASO Visual Abstract

Financial Toxicity Among Women with Breast Cancer Varies by Age and Race

Breast Oncology

Single Port Robotic Liver Resection: Metastasectomy for Recurrent Fibrolamellar Hepatocellular Carcinoma

Hepatobiliary Tumors

ASO Visual Abstract: The Rise of Patients Declining Rectal Cancer Surgery in the Era of Total Neoadjuvant Therapy

ASO Visual Abstract

The Rise of Patients Declining Rectal Cancer Surgery in the Era of Total Neoadjuvant Therapy

Colorectal Cancer

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

29.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Bisher wird für den interventionellen Mitralklappenersatz standardmäßig der transapikale Zugangsweg gewählt. In einer Registeranalyse hat dieser in puncto Sicherheit allerdings den Kürzeren gezogen.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

24.04.2025
Colitis ulcerosa
Nachrichten

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rates of Pathologic Complete Response and Overall Survival in Patients with Inflammatory Breast Cancer: A National Cancer Database Study

Abstract

Background

Methods

Results

Conclusion

Weitere Artikel der Ausgabe 12/2024

Effectiveness of Prehabilitation Modalities on Postoperative Outcomes Following Colorectal Cancer Surgery: A Systematic Review of Randomised Controlled Trials

ASO Visual Abstract: Temporal Trends in Survival Outcomes for Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy: A 14-Year Analysis

Financial Toxicity Among Women with Breast Cancer Varies by Age and Race

Single Port Robotic Liver Resection: Metastasectomy for Recurrent Fibrolamellar Hepatocellular Carcinoma

ASO Visual Abstract: The Rise of Patients Declining Rectal Cancer Surgery in the Era of Total Neoadjuvant Therapy

The Rise of Patients Declining Rectal Cancer Surgery in the Era of Total Neoadjuvant Therapy

Neu im Fachgebiet Chirurgie

Welcher Zugangsweg ist besser für den interventionellen Mitralklappenersatz?

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Appendektomie erhält Remission bei Colitis ulcerosa

Update Chirurgie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten